Information Provided By: 
Fly News Breaks for May 8, 2017
CYTK
May 8, 2017 | 08:59 EDT
JMP Securities analyst Jason Butler says that the approval of Radicava for ALS bodes well for Cytokinetics' ALS treatment, tirasemtiv, assuming that the latter drug shows positive results in an ongoing Phase 3 trial. The analyst thinks that .Radicava "can enhance the commercial prospects for tirasemtiv without representing direct competition." He keeps a $17 price target and an Outperform rating on the shares.
News For CYTK From the Last 2 Days
There are no results for your query CYTK
